Freeman Chris 4

What Happened
Chris Freeman, Chief Commercial Officer of Guardant Health (GH), was granted 18,744 restricted stock units (RSUs) on March 11, 2026. The award was recorded as an acquisition at $0.00 (typical for RSU grants); no cash changed hands at grant.

Key Details

• Transaction type: A (award/grant) — 18,744 RSUs granted on 2026-03-11 at $0.00 per share.
• Vesting: 33% vests on April 1, 2027; the remaining 67% vests in equal quarterly installments over the following two-year period (see footnote F1).
• Shares owned after transaction: Not specified in the Form 4.
• Tax/withholding note: Footnote F2 indicates "Not applicable for Restricted Stock Units."
• Filing: Form 4 filed 2026-03-13 (appears timely relative to the 2026-03-11 grant).

Context
This was a compensation award (RSUs), not an open-market purchase or sale. RSU grants are common executive compensation and vest over time, so they do not represent an immediate sale or purchase signal. The reported transaction is a derivative award that converts to ordinary shares as the RSUs vest.